May 12 2022

Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB

By |2022-05-11T18:58:14-04:00May 12th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange.  Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 ...

Apr 27 2022

Dr. Gregg Sturrus’ TEDx Talk Features Halberd’s Extracorporeal Treatment of Neurodegenerative Diseases

By |2022-04-27T16:28:20-04:00April 27th, 2022|Medical, News, Videos|0 Comments

Jackson Center, PA, April 27, 2022 – A key member of Halberd Corporation’s (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® on Halberd’s patented and patent-pending extracorporeal elimination of neurodegenerative disease proteins and cytokines using lasers and metallic nanoparticles. Dr. Sturrus, in his talk, provided a brief ...

Apr 25 2022

Halberd CEO Letter

By |2022-04-24T18:20:33-04:00April 25th, 2022|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...

Apr 18 2022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

By |2022-04-17T19:16:30-04:00April 18th, 2022|Featured, Investor News, Medical, Press Releases|0 Comments

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states.  The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes.  This ...

Apr 11 2022

Halberd Entering the Medical Metaverse(TM)

By |2022-04-10T18:42:06-04:00April 11th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in ...

Apr 4 2022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

By |2022-04-05T20:32:09-04:00April 4th, 2022|Investor News, Medical, News, Press Releases|Comments Off on Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro.  Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...

Mar 25 2022

Halberd Corporation Brief Overview

By |2022-03-25T09:57:20-04:00March 25th, 2022|Featured, News|Comments Off on Halberd Corporation Brief Overview

Halberd Corporation Brief Overview Halberd Corporation was re-formed in May 2020.  Noting that Halberd’s unique extracorporeal technological approach is adaptable to many disease states, Halberd’s team of professionals employed its skills, resources and focus to concentrate on developing treatments against some of the world’s more persistent diseases, such as, Alzheimer’s Disease, PTSD, ...

Mar 16 2022

Infectious Disease Specialist Will Guide Halberd’s Extracorporeal Elimination of Disease Antigens in Animals and Then Humans

By |2022-03-15T22:01:14-04:00March 16th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research.  To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and ...

Mar 8 2022

Halberd Expands Its Technical Expertise With the Addition of Microbiology Professor

By |2022-03-07T23:31:23-05:00March 8th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team.  Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University.  Dr. Cooper has been a valuable resource in Halberd’s work at ...

Mar 1 2022

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant

By |2022-03-01T10:07:25-05:00March 1st, 2022|Featured, Investor News, Medical, News|0 Comments

Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen.  The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies.  The results are shown ...

Go to Top